Full Press Release Details
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS.
BIIB
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Key Takeaway: Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Price reaction · baseline $266.15 (2023-03-21 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
-1.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis